J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
Joan Bladé,Pieter Sonneveld,Jesús F. San Miguel,Heather J. Sutherland,Roman Hájek,Arnon Nagler,Andrew Spencer,Tadeusz Robak,Keith C. Lantz,Sen H. Zhuang,Jean Luc Harousseau,Robert Z. Orlowski +11 more
TL;DR: Treatment of relapsed/refractory myeloma with the combination of PLD plus bortezomib provides better outcomes over bortzomib alone, even in the presence of high-risk prognostic factors.
Journal ArticleDOI
Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients.
Thierry Facon,Jean Yves Mary,C. Hulin,Lofti Benboubker,Michel Attal,Jean Luc Harousseau,Brigitte Pegourie,Marc Renaud,Gaelle Guillerm,Laurent Voillat,Carine Chaleteix,Jacques Troncy,Mathieu Monconduit,Philippe Casassus,Hervé Maisonneuve,Véronique Dorvaux,Jérôme Jaubert,Mamoun Dib,Chantal Doyen +18 more
TL;DR: The experts considered that the adverse events were as expected with the treatments used and no clear-cut advantage or disadvantage of either MP-THAL or MEL100 over MP was observed according to the statistical rule of the first interim analysis and the trial should pursue as planned.
Journal ArticleDOI
Bone-marrow transplantation for sickle-cell anaemia
David J. Weatherall,Christiane Vermylen,E Fernandez Robles,J. Ninane,Guy Cornu,N. Milpied,Jean Luc Harousseau,R. Garand,A. David +8 more
TL;DR: Bone marrow transplantation represents an attractive therapeutic tool and its role in other haemoglobinopathies like thalassaemia is now well demonstrated and the patient is now cured of both the sickle cell anaemia and the leukemia.
Journal ArticleDOI
Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)
Brian G.M. Durie,Robert A. Kyle,Andrew R. Belch,William I. Bensinger,Joan Bladé,Mario Boccadoro,J. Anthony Child,Raymond L. Comenzo,Ben Djulbegovic,Dorotea Fantl,Gösta Gahrton,Jean Luc Harousseau,Vania Hungria,Douglas E. Joshua,Heinz Ludwig,Jayesh Mehta,Angelina Rodrique Morales,Gareth J. Morgan,Amara Nouel,Martin M. Oken,R. L. Powles,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Seema Singhal,Bhawna Sirohi,Pieter Sonneveld,Guido Tricot,Brian G Van Ness +28 more
Journal ArticleDOI
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
Jatin P. Shah,Joan Bladé,Pieter Sonneveld,Jean Luc Harousseau,Keith C. Lantz,Anil Londhe,Colin Lowery,Robert Z. Orlowski +7 more
TL;DR: A rapid and early monoclonal protein response during initial therapy in patients with multiple myeloma had been identified as a predictor of superior long‐term outcome in some—but not all—studies.